SEARCH

SEARCH BY CITATION

REFERENCES

  • 1
    Chang CN, Skalski V, Zhou JH, Cheng YC. Biochemical pharmacology of (+)- and (−)-2′,3′-dideoxy-3′-thiacytidine as anti-hepatitis B virus agents. J Biol Chem 1992; 31:2241422420.
  • 2
    Chang CN, Doong SL, Zhou JH, Beach JW, Jeong LS, Chu CK, Tsai CH, et al. Deoxycytidine deaminase-resistant stereoisomer is the active form of (+/−)-2′,3′-dideoxy-3′-thiacytidine in the inhibition of hepatitis B virus replication. J Biol Chem 1992; 20:1393813942.
  • 3
    Doong SL, Tsai CH, Schinazi RF, Liotta DC, Cheng YC. Inhibition of the replication of hepatitis B virus in vitro by 2′,3′-dideoxy-3′-thiacytidine and related analogues. Proc Natl Acad Sci U S A 1991; 19:84958499.
  • 4
    Charvet AS, Turin F, Faury P, Hantz O, Camplo M, Mourier N, Berthillon P, et al. Synthesis and antiviral activity of new carbonylphosphonate 2′,3′-dideoxy-3′-thiacytidine conjugates. Antiviral Res 1994; 2:161168.
  • 5
    Mansour TS, Jin H, Wang W, Hooker EU, Ashman C, Cammack N, Salomon H, et al. Anti-human immunodeficiency virus and anti-hepatitis-B virus activities and toxicities of the enantiomers of 2′-deoxy-3′-oxa-4′-thiocytidine and their 5-fluoro analogues in vitro. J Med Chem 1995; 1:14.
  • 6
    Severni A, Liu X, Wilson JS, Tyrrell DL. Mechanism of inhibition of duck hepatitis B virus polymerase by (−)-β-L-2′,3′-dideoxy -3′-thiacytidine. Antimicrob Agents Chemother 1995; 39:14301435.MEDLINE
  • 7
    Korba BE. In vitro evaluation of combination therapies against hepatitis B virus replication. Antiviral Res 1995; 29:4951.
  • 8
    Fischer KP, Tyrrell DL. Generation of duck hepatitis B virus polymerase mutants through site-directed mutagenesis which demonstrate resistance to lamivudine [(−)-β-L-2′,3′-dideoxy -3′-thiacytidine] in vitro. Antimicrob Agents Chemother 1996; 40:9571960.
  • 9
    Xie H, Voronkov M, Liotta DC, Korba BA, Schinazi RF, Richman DD, Hostetler KY. Phosphatidy1-2′,3′-dideoxy-3′-thiacytidine:synthesis and activity in hepatitis B- and HIV-1-infected cells. Antiviral Res 1995; 28:113120.MEDLINE
  • 10
    Pajagopalan P, Boudinot F, Chu CK, Tennant BC, Baldwin BH, Schinazi RF. Pharmacokinetics of (−)-2′-3′-dideoxy-3′-thiacytidine in woodchucks. Antimicrob Agents Chemother 1996; 40:642645.MEDLINE
  • 11
    Lai CL, Ching CK, Tung AK, Li E, Young J, Hill A, Wong BC, Dent J, et al. Lamivudine is effective in suppressing hepatitis B virus DNA in Chinese hepatitis B surface antigen carriers: a placebo-controlled trial. Hepatology 1997; 1:241244.
  • 12
    Benhamou Y, Katlama C, Lunel F, Coutellier A, Dohin E, Hamm N, Tubiana R, et al. Effects of lamivudine on replication of hepatitis B virus in HIV-infected men. Ann Intern Med 1996; 125:705712.MEDLINE
  • 13
    Ben-Ari Z, Shmueli D, Mor E, Shapira Z, Tur-Kaspa R. Beneficial effect of lamivudine in recurrent hepatitis B after liver transplantation. Transplantation 1997; 3:393396.
  • 14
    Grellier L, Mutimer D, Ahmed M, Brown D, Burroughs AK, Rolles K, McMaster P, et al. Lamivudine prophylaxis against reinfection in liver transplantation for hepatitis B cirrhosis. Lancet 1996; 9036:12121215.
  • 15
    Benhamou Y, Dohin E, Lunel-Fabiani F, Poynard T, Huraux JM, Katlama C, Opolon P, et al. Efficacy of lamivudine on replication of hepatitis B virus in HIV-infected patients [Letter]. Lancet 1995; 8946:396397.
  • 16
    Schnittman SM, Pierce PF. Potential role of lamivudine (3TC) in the clearance of immunodeficiency virus type. Clin Infect Dis 1996; 3:638639.
  • 17
    Schalm SW, de Man RA, Heijtink RA, Niesters HG. New nucleoside analogues for chronic hepatitis B. J Hepatol 1995; 1:5256.
  • 18
    Hoofnagle JH, Lau D. New therapies for chronic hepatitis B. J Viral Hepat 1997; 4(Suppl 1:4150.MEDLINE
  • 19
    Grellier L, Dusheiko GM. Hepatitis B virus and liver transplantation: concepts in antiviral prophylaxis. J Viral Hepat 1997; (Suppl 1):111116.
  • 20
    Honkoop P, de Man RA, Zondervan PE, Schalm SW. Histological improvement in patients with chronic hepatitis B virus infection treated with lamivudine. Liver 1997; 2:103106.
  • 21
    Bain VG, Kneteman NM, Ma MM, Gutfreund K, Shapiro JA, Fischer K, Tipples G, et al. Efficacy of lamivudine in chronic hepatitis B patients with active viral replication and decompensated cirrhosis undergoing liver transplantation. Transplantation 1996; 10:14561462.
  • 22
    Dienstag JL, Perrillo RP, Schiff ER, Bartholomew M, Vicary C, Rubin M. A preliminary trial of lamivudine for chronic hepatitis B infection. N Engl J Med 1995; 25:16571661.
  • 23
    Balzarini J, Wedgwood O, Kruining J, Pelemans H, Heijtink R, De Clercq E, McGuigan C. Anti-HIV and anti-HBV activity and resistance profile of 2′,3′- dideoxy-3′-thiacytidine (3TC) and its arylphosphoramidate derivative CF 1109. Biochem Biophys Res Commun 1996; 2:363369.
  • 24
    Bartholomew MM, Jansen RW, Jeffers LJ, Reddy KR, Johnson LC, Bunzendahl H, Condreay LD, et al. Hepatitis-B-virus resistance to lamivudine given for recurrent infection after orthotopic liver transplantation [Comments]. Lancet 1997; 9044:2022.
  • 25
    Ling R, Mutimer D, Ahmed M, Boxall EH, Elias E, Dusheiko GM, Harrison TJ. Selection of mutations in the hepatitis B virus polymerase during therapy of transplant recipients with lamivudine. Hepatology 1996; 3:711713.
  • 26
    Tipples GA, Ma MM, Fischer KP, Bain VG, Kneteman NM, Tyrrell DL. Mutation in HBV RNA–dependent DNA polymerase confers resistance to lamivudine in vivo. Hepatology 1996; 3:714717.
  • 27
    Naoumov NV, Smith C, Williams R. Emergence and characterization of lamivudine resistant hepatitis B virus variant. Hepatology 1996; 24:282.
  • 28
    Schalm SW. Clinical implications of lamivudine resistance by HBV. Lancet 1997; 9044:34.
  • 29
    Honkoop P, Niesters HG, de Man RA, Osterhaus AD, Schalm SW. Lamivudine resistance immunocompetent chronic hepatitis B. J Hepatol 1997; 26:13931395.MEDLINE
  • 30
    Lai CL, Liaw YF, Leung NWY, Deslauriers M, Barnard J, Sanathanan L, Gray DF, et al. Genotypic resistance to lamivudine in a prospective, placebo-controlled multicentre study in Asia of lamivudine therapy for chronic hepatitis B infection: incidence, kinetics of emergence, and correlation with disease parameters [Abstract]. Hepatology 1997; 26:259A.
  • 31
    Ono Y, Onda H, Sasada R, Igarashi K, Sugino Y, Nishioka K. The complete nucleotide sequences of the cloned hepatitis B virus DNA; subtype adr and adw. Nucleic Acids Res 1983; 11:17471757.MEDLINE
  • 32
    Kwok S, Higuchi R. Avoiding false positives with PCR. Nature 1989; 339:237238.MEDLINE
  • 33
    Back NT, Nijhhuis M, Kulen W, Boucher CA, Essink BB, Kuilenburg AB, Gennip AH, Berkhout B. Reduced replication of 3TC-resistant HIV-1 Variants in primary cells due to a processivity defect of the reverse transcriptase enzyme. EMBO J 1996; 15:40404049.MEDLINE